Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Abdominal Radiology
Erschienen in:

22.10.2016

Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology

verfasst von: Daniel I. Glazer, Elmira Hassanzadeh, Andriy Fedorov, Olutayo I. Olubiyi, Shayna S. Goldberger, Tobias Penzkofer, Trevor A. Flood, Paul Masry, Robert V. Mulkern, Michelle S. Hirsch, Clare M. Tempany, Fiona M. Fennessy

Erschienen in: Abdominal Radiology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Objective

To determine if tumor cell density and percentage of Gleason pattern within an outlined volumetric tumor region of interest (TROI) on whole-mount pathology (WMP) correlate with apparent diffusion coefficient (ADC) values on corresponding TROIs outlined on pre-operative MRI.

Methods

Men with biopsy-proven prostate adenocarcinoma undergoing multiparametric MRI (mpMRI) prior to prostatectomy were consented to this prospective study. WMP and mpMRI images were viewed using 3D Slicer and each TROI from WMP was contoured on the high b-value ADC maps (b0, 1400). For each TROI outlined on WMP, TCD (tumor cell density) and the percentage of Gleason pattern 3, 4, and 5 were recorded. The ADCmean, ADC10th percentile, ADC90th percentile, and ADCratio were also calculated in each case from the ADC maps using 3D Slicer.

Results

Nineteen patients with 21 tumors were included in this study. ADCmean values for TROIs were 944.8 ± 327.4 vs. 1329.9 ± 201.6 mm2/s for adjacent non-neoplastic prostate tissue (p < 0.001). ADCmean, ADC10th percentile, and ADCratio values for higher grade tumors were lower than those of lower grade tumors (mean 809.71 and 1176.34 mm2/s, p = 0.014; 10th percentile 613.83 and 1018.14 mm2/s, p = 0.009; ratio 0.60 and 0.94, p = 0.005). TCD and ADCmean (ρ = −0.61, p = 0.005) and TCD and ADC10th percentile (ρ = −0.56, p = 0.01) were negatively correlated. No correlation was observed between percentage of Gleason pattern and ADC values.

Conclusion

DWI MRI can characterize focal prostate cancer using ADCratio, ADC10th percentile, and ADCmean, which correlate with pathological tumor cell density.
Literatur
1.
Cancer Facts & Figures (2016) American Cancer Society, Atlanta
2.
Wilt TJ, Brawer MK, Jones KM, et al. (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367(3):203–213CrossRefPubMedPubMedCentral
3.
Hamdy FC, Donovan JL, Lane JA, et al. (2016) 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med . doi:10.​1056/​NEJMoa1606221
4.
Dinh KT, Mahal BA, Ziehr DR, et al. (2015) Incidence and predictors of upgrading and up staging among 10,000 contemporary patients with low risk prostate cancer. J Urol 194(2):343–349CrossRefPubMed
5.
Dinh KT, Muralidhar V, Mahal BA, et al. (2015) Occult high-risk disease in clinically low-risk prostate cancer with ≥50% positive biopsy cores: should national guidelines stop calling them low-risk? Urology . doi:10.​1016/​j.​urology.​2015.​08.​026 PubMed
6.
Barry MJ, Gallagher PM, Skinner JS, Fowler FJ (2012) Adverse effects of robotic-assisted laparoscopic versus open retropubic radical prostatectomy among a nationwide random sample of medicare-age men. J Clin Oncol 30(5):513–518CrossRefPubMedPubMedCentral
7.
Ploussard G, Epstein JI, Montironi R, et al. (2011) The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 60(2):291–303CrossRefPubMed
8.
Stark JR, Perner S, Stampfer MJ, et al. (2009) Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27(21):3459–3464CrossRefPubMedPubMedCentral
9.
Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT (2007) Imaging prostate cancer: a multidisciplinary perspective. Radiology 243(1):28–53CrossRefPubMed
10.
Turkbey B, Brown AM, Sankineni S, et al. (2015) Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer. CA Cancer J Clin 40(7):2557–2565
11.
Glazer DI, Davenport MS, Khalatbari S, et al. (2015) Mass-like peripheral zone enhancement on CT is predictive of higher-grade (Gleason 4 + 3 and higher) prostate cancer. Abdom Imaging 40(3):560–570CrossRefPubMed
12.
13.
14.
Ankerst DP, Hoefler J, Bock S, et al. (2014) Prostate cancer prevention trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology 83(6):1362–1367CrossRefPubMedPubMedCentral
15.
Kweldam CF, Wildhagen MF, Steyerberg EW, et al. (2015) Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod Pathol 28(3):457–464CrossRefPubMed
16.
Dong F, Yang P, Wang C, et al. (2013) Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma. Am J Surg Pathol 37(12):1855–1861CrossRefPubMed
17.
Radtke JP, Schwab C, Wolf MB, et al. (2016) Multiparametric magnetic resonance imaging (MRI) and MRI-transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen. Eur Urol . doi:10.​1016/​j.​eururo.​2015.​12.​052
18.
Delongchamps NB, Lefèvre A, Bouazza N, et al. (2015) Detection of significant prostate cancer with magnetic resonance targeted biopsies–should transrectal ultrasound-magnetic resonance imaging fusion guided biopsies alone be a standard of care? J Urol 193(4):1198–1204CrossRefPubMed
19.
Weinreb JC, Barentsz JO, Choyke PL, et al. (2016) PI-RADS Prostate Imaging–Reporting and Data System: 2015, Version 2. Eur Urol 69(1):16–40CrossRefPubMed
20.
Vargas HA, Akin O, Franiel T, et al. (2011) Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 259(3):775–784CrossRefPubMedPubMedCentral
21.
Kim TH, Jeong JY, Lee SW, et al. (2015) Diffusion-weighted magnetic resonance imaging for prediction of insignificant prostate cancer in potential candidates for active surveillance. Eur Radiol 25(6):1786–1792CrossRefPubMed
22.
Boesen L, Chabanova E, Løgager V, Balslev I, Thomsen HS (2015) Apparent diffusion coefficient ratio correlates significantly with prostate cancer gleason score at final pathology. J Magn Reson Imaging 42(2):446–453CrossRefPubMed
23.
Hambrock T, Somford DM, Huisman HJ, et al. (2011) Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 259(2):453–461CrossRefPubMed
24.
Mazaheri Y, Shukla-Dave A, Hricak H, et al. (2008) Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging—correlation with pathologic findings. Radiology 246(2):480–488CrossRefPubMed
25.
Oto A, Kayhan A, Jiang Y, et al. (2010) Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 257(3):715–723CrossRefPubMed
26.
Donati OF, Mazaheri Y, Afaq A, et al. (2014) Prostate cancer aggressiveness: assessment with whole-lesion histogram analysis of the apparent diffusion coefficient. Radiology 271(1):143–152CrossRefPubMed
27.
Rosenkrantz AB, Triolo MJ, Melamed J, et al. (2015) Whole-lesion apparent diffusion coefficient metrics as a marker of percentage Gleason 4 component within Gleason 7 prostate cancer at radical prostatectomy. J Magn Reson Imaging 41(3):708–714CrossRefPubMed
28.
Fedorov A, Penzkofer T, Hirsch MS, et al. (2015) The role of pathology correlation approach in prostate cancer index lesion detection and quantitative analysis with multiparametric MRI. Acad Radiol 22(5):548–555CrossRefPubMedPubMedCentral
29.
Fennessy FM, Fedorov A, Penzkofer T, et al. (2015) Quantitative pharmacokinetic analysis of prostate cancer DCE-MRI at 3T: comparison of two arterial input functions on cancer detection with digitized whole mount histopathological validation. Magn Reson Imaging 33(7):886–894CrossRefPubMedPubMedCentral
30.
Hegde JV, Mulkern RV, Panych LP, et al. (2013) Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer. J Magn Reson Imaging 37(5):1035–1054CrossRefPubMedPubMedCentral
31.
Trivedi H, Turkbey B, Rastinehad AR, et al. (2012) Use of patient-specific MRI-based prostate mold for validation of multiparametric MRI in localization of prostate cancer. Urology 79(1):233–239CrossRefPubMedPubMedCentral
32.
Fedorov A, Beichel R, Kalpathy-Cramer J, et al. (2012) 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging 30(9):1323–1341CrossRefPubMedPubMedCentral
33.
Jonmarker S, Valdman A, Lindberg A, Hellström M, Egevad L (2006) Tissue shrinkage after fixation with formalin injection of prostatectomy specimens. Virchows Arch 449(3):297–301CrossRefPubMed
34.
Stamey TA, Freiha FS, McNeal JE, et al. (1993) Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71(3 Suppl):933–938CrossRefPubMed
35.
Wolters T, Roobol MJ, van Leeuwen PJ, et al. (2011) A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 185(1):121–125CrossRefPubMed
36.
Kuwano H, Miyazaki T, Tsutsumi S, et al. (2004) Cell density modulates the metastatic aggressiveness of a mouse colon cancer cell line, colon 26. Oncology 67(5–6):441–449PubMed
37.
Pernicová Z, Slabáková E, Fedr R, et al. (2014) The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells. Mol Cancer 13:113CrossRefPubMedPubMedCentral
38.
Tollefson MK, Leibovich BC, Slezak JM, Zincke H, Blute ML (2006) Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol 175(2):547–551CrossRefPubMed
39.
Vargas HA, Hötker AM, Goldman DA, et al. (2015) Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. Eur Radiol . doi:10.​1007/​s00330-015-4015-6
40.
Gibbs P, Liney GP, Pickles MD, et al. (2009) Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Investig Radiol 44(9):572–576CrossRef
41.
Zelhof B, Pickles M, Liney G, et al. (2009) Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int 103(7):883–888CrossRefPubMed
42.
Chatterjee A, Watson G, Myint E, et al. (2015) Changes in epithelium, stroma, and lumen space correlate more strongly with Gleason Pattern and are stronger predictors of prostate ADC changes than cellularity metrics. Radiology 277(3):751–762CrossRefPubMed
43.
Bollineni VR, Kramer G, Liu Y, Melidis C, deSouza NM (2015) A literature review of the association between diffusion-weighted MRI derived apparent diffusion coefficient and tumour aggressiveness in pelvic cancer. Cancer Treat Rev 41(6):496–502CrossRefPubMed
44.
Turkbey B, Shah VP, Pang Y, et al. (2011) Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 258(2):488–495CrossRefPubMedPubMedCentral
Metadaten
Titel
Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology
verfasst von
Daniel I. Glazer
Elmira Hassanzadeh
Andriy Fedorov
Olutayo I. Olubiyi
Shayna S. Goldberger
Tobias Penzkofer
Trevor A. Flood
Paul Masry
Robert V. Mulkern
Michelle S. Hirsch
Clare M. Tempany
Fiona M. Fennessy
Publikationsdatum
22.10.2016
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 3/2017
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-016-0942-1

Weitere Artikel der Ausgabe 3/2017

Oral contrast utilization for abdominal/pelvic CT scanning in today’s emergency room setting

  • Commentary

Corkscrew esophagus

  • Classics in Abdominal Imaging

The northern exposure sign

  • Classics in Abdominal Imaging

Lymphoepithelial cyst of pancreas: spectrum of radiological findings with pathologic correlation

  • Review Paper

Right colonic diverticulitis in Caucasians: presentation and outcomes versus left-sided disease

“How to” incorporate dual-energy imaging into a high volume abdominal imaging practice

  • Invited article

Neu im Fachgebiet Radiologie

Stumme Schlaganfälle − ein häufiger Nebenbefund im Kopf-CT?

In 4% der in der Notfallambulanz initiierten zerebralen Bildgebung sind „alte“ Schlaganfälle zu erkennen. Gar nicht so selten handelt es sich laut einer aktuellen Studie dabei um unbemerkte Insulte. Bietet sich hier womöglich die Chance auf ein effektives opportunistisches Screening?

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Stören weiße Wände und viel Licht die Bildqualitätskontrolle?

Wenn es darum geht, die technische Qualität eines Mammogramms zu beurteilen, könnten graue Wandfarbe und reduzierte Beleuchtung im Bildgebungsraum von Vorteil sein. Darauf deuten zumindest Ergebnisse einer kleinen Studie hin. 

PMBCL mit CMR: Radiatio kann ohne Risiko weggelassen werden

Patienten mit primär mediastinalem B-Zell-Lymphom (PMBCL), die nach der Induktionstherapie eine komplette metabolische Remission (CMR) erreichen und keine konsolidierende Bestrahlung erhalten, müssen offenbar keine Überlebensnachteile fürchten.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise